Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04162210




Registration number
NCT04162210
Ethics application status
Date submitted
11/11/2019
Date registered
14/11/2019

Titles & IDs
Public title
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Scientific title
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Secondary ID [1] 0 0
2018-004252-38
Secondary ID [2] 0 0
207495
Universal Trial Number (UTN)
Trial acronym
DREAMM-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Belantamab mafodotin
Treatment: Drugs - Pom/dex (Pomalidomide plus low dose Dexamethasone)

Experimental: Participants receiving Belantamab mafodotin - Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W

Active comparator: Participants receiving pom/dex - Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.


Treatment: Drugs: Belantamab mafodotin
Belantamab mafodotin will be administered.

Treatment: Drugs: Pom/dex (Pomalidomide plus low dose Dexamethasone)
Pomalidomide and Dexamethasone will be administered.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) Based on Investigator-assessed Response as Per International Myeloma Working Group (IMWG)
Timepoint [1] 0 0
Up to 27 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
60 months
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
Up to 55 months
Secondary outcome [3] 0 0
Clinical Benefit Rate (CBR)
Timepoint [3] 0 0
Up to 55 months
Secondary outcome [4] 0 0
Duration of Response (DoR)
Timepoint [4] 0 0
Up to 55 months
Secondary outcome [5] 0 0
Time to Response (TTR)
Timepoint [5] 0 0
Up to 55 months
Secondary outcome [6] 0 0
Time to Progression (TTP)
Timepoint [6] 0 0
Up to 55 months
Secondary outcome [7] 0 0
Number of Participants With Adverse Events (AEs)
Timepoint [7] 0 0
Up to 55 months
Secondary outcome [8] 0 0
Change From Baseline in Hematology Parameters: Absolute White Blood Cell Count (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, and Neutrophils (Giga Cells Per Liter)
Timepoint [8] 0 0
Baseline and up to 55 months
Secondary outcome [9] 0 0
Change From Baseline in Hematology Parameters: Red Blood Cell (RBC) Count and Reticulocyte Count (Trillion Cells Per Liter)
Timepoint [9] 0 0
Baseline and up to 55 months
Secondary outcome [10] 0 0
Change From Baseline in Hematology Parameters: Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Grams Per Liter)
Timepoint [10] 0 0
Baseline and up to 55 months
Secondary outcome [11] 0 0
Change From Baseline in Hematology Parameters: Hematocrit (Proportion of Red Blood Cells in Blood)
Timepoint [11] 0 0
Baseline and up to 55 months
Secondary outcome [12] 0 0
Change From Baseline in Hematology Parameters: Mean Corpuscular Volume (MCV) [Femtoliter]
Timepoint [12] 0 0
Baseline and up to 55 months
Secondary outcome [13] 0 0
Change From Baseline in Hematology Parameters: Mean Corpuscular Hemoglobin (MCH) [Picograms]
Timepoint [13] 0 0
Baseline and up to 55 months
Secondary outcome [14] 0 0
Change From Baseline in Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH)
Timepoint [14] 0 0
Baseline and up to 55 months
Secondary outcome [15] 0 0
Change From Baseline in Clinical Chemistry Parameters: Calcium, Chloride, Glucose, Potassium, Sodium, Magnesium, Blood Urea Nitrogen (BUN), and Phosphorous (Millimoles Per Liter)
Timepoint [15] 0 0
Baseline and up to 55 months
Secondary outcome [16] 0 0
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Total Bilirubin, Uric Acid (Micromoles Per Liter)
Timepoint [16] 0 0
Baseline and up to 55 months
Secondary outcome [17] 0 0
Change From Baseline in Clinical Chemistry Parameters: Albumin and Total Protein (Grams Per Liter)
Timepoint [17] 0 0
Baseline and up to 55 months
Secondary outcome [18] 0 0
Change From Baseline in Urinalysis Parameter: Specific Gravity (Ratio)
Timepoint [18] 0 0
Baseline and up to 55 months
Secondary outcome [19] 0 0
Change From Baseline in Urinalysis Parameters- Urine Potential of Hydrogen (pH) (Points on a Scale)
Timepoint [19] 0 0
Baseline and up to 55 months
Secondary outcome [20] 0 0
Change From Baseline in Urinalysis Parameter: Glucose (Millimole Per Liter)
Timepoint [20] 0 0
Baseline and up to 55 months
Secondary outcome [21] 0 0
Change From Baseline in Urinalysis Parameter: Protein (Grams Per Liter)
Timepoint [21] 0 0
Baseline and up to 55 months
Secondary outcome [22] 0 0
Change From Baseline in Urinalysis Parameter: Ketones (Millimoles Per Liter)
Timepoint [22] 0 0
Baseline and up to 55 months
Secondary outcome [23] 0 0
Change From Baseline in Urinalysis Parameter: Blood (10^9 Cells Per Liter)
Timepoint [23] 0 0
Baseline and up to 55 months
Secondary outcome [24] 0 0
Change From Baseline in Urinalysis Parameter: Creatinine/Albumin Ratio (Ratio)
Timepoint [24] 0 0
Baseline and up to 55 months
Secondary outcome [25] 0 0
Number of Participants With Abnormal Ocular Findings
Timepoint [25] 0 0
Up to 55 months
Secondary outcome [26] 0 0
Plasma Concentrations of Belantamab Mafodotin
Timepoint [26] 0 0
Up to 55 months
Secondary outcome [27] 0 0
Plasma Concentrations of Total Monoclonal Antibody (mAb)
Timepoint [27] 0 0
Up to 55 months
Secondary outcome [28] 0 0
Plasma Concentrations of Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)
Timepoint [28] 0 0
Up to 55 months
Secondary outcome [29] 0 0
Number of Participants With Anti-drug Antibody (ADAs) Against Belantamab Mafodotin
Timepoint [29] 0 0
Up to 55 months
Secondary outcome [30] 0 0
Titer of ADAs Against Belantamab Mafodotin
Timepoint [30] 0 0
Up to 55 months
Secondary outcome [31] 0 0
Number of Participants With Symptomatic Adverse Effects Measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Timepoint [31] 0 0
Up to 55 months
Secondary outcome [32] 0 0
Number of Participants With Symptomatic Adverse Effects Measured by Ocular Surface Disease Index (OSDI)
Timepoint [32] 0 0
Up to 55 months
Secondary outcome [33] 0 0
European Organization for Research and Treatment of Cancer IL52 (EORTC IL52) Score
Timepoint [33] 0 0
Up to 55 months
Secondary outcome [34] 0 0
Rate of Minimal Residual Disease (MRD)
Timepoint [34] 0 0
Up to 55 months

Eligibility
Key inclusion criteria
* Capable of giving signed informed consent.
* Participants must be 18 or older, at the time of signing the informed consent. In Republic of Korea, participants must be over 19 years of age inclusive, at the time of signing informed consent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
* Histologically or cytologically confirmed diagnosis of Multiple myeloma (MM) as defined according to IMWG, and : Has undergone autologous stem cell transplant (SCT), or is considered transplant ineligible; Has received at least 2 prior lines of anti-myeloma treatments, including at least 2 consecutive cycles of both lenalidomide and a proteasome inhibitor (given separately or in combination), and must have documented disease progression on, or within 60 days of, completion of the last treatment or must be non-responsive while on last treatment, where non-responsive is defined as not achieving at least Minimal Response (MR) after 2 complete treatment cycles. In such cases lack of achieving of at least MR must be determined no earlier than at least 4 weeks after the last treatment.
* Has measurable disease with at least one of the following: Serum M-protein >=0.5 gram per deciliter (g/dL) (>=5 gram per Liter); Urine M-protein >=200 mg/24 hours; Serum free light chain (FLC) assay: Involved FLC level >=10 milligram per deciliter (mg/dL) (>=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).
* Participants with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met: Transplant was >100 days prior to initiating study treatment; No active infection(s).
* Adequate organ system functions as defined: Absolute neutrophil count (ANC) >=1.0*10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 50x10^9/L; Total bilirubin <=1.5* Upper limit of normal (ULN) (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent); ALT <=2.5*ULN; Estimated glomerular filtration rate (eGFR) >=30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2); Spot urine (albumin/creatinine ratios) <=500 milligram per gram (mg/g) (56 milligram per millimoles [mg/mmol]).
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and until 6 months after the last dose of study intervention to allow for clearance of any altered sperm: Refrain from donating sperm PLUS, either: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below depending on whether they are randomised to Arm 1 (belantamab mafodotin) or Arm 2 (pom/dex), even if they have undergone a successful vasectomy: Agree to use a male condom throughout study treatment including the 6 month follow-up period even if they have undergone a successful vasectomy and a female partner to use an additional highly effective contraceptive method with a failure rate of <1 percent per year when having sexual intercourse with a pregnant woman or a woman of childbearing potential who is not currently pregnant. Four weeks for male participants on Treatment Arm 2 (pom/dex).
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and agrees to abide by the following: Arm 1 (belantamab mafodotin): Use a contraceptive method that is highly effective (with a failure rate of <1 percent per year) which includes abstinence, preferably with low user dependency during the intervention period and for 4 months after the last dose of study treatment. Arm 2 (pom/dex): Due to pomalidomide being a thalidomide analogue with risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, WOCBP participants will be eligible if they commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control (one method that is highly effective), beginning 4 weeks prior to initiating treatment with pomalidomide, during therapy, during dose interruptions and continuing for at least 4 weeks following discontinuation of pomalidomide treatment. Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing pomalidomide therapy. And agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should confirm the effectiveness of the contraceptive method(s) ahead of the first dose of study intervention.
* All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events [NCI-CTCAE], version 5.0, 2017) must be <=Grade 1 at the time of enrollment, except for alopecia and Grade 2 peripheral neuropathy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes); active plasma cell leukemia at the time of screening.
* Systemic anti-myeloma therapy or use of an investigational drug within <14 days or 5 half-lives, whichever is shorter, before the first dose of study intervention.
* Prior treatment with an anti-MM monoclonal antibody within 30 days prior to receiving the first dose of study intervention.
* Prior B cell maturation antigen (BCMA)-targeted therapy or prior pomalidomide treatment.
* Plasmapheresis within 7 days prior to the first dose of study intervention.
* Prior allogeneic stem cell transplant. (Participants who have undergone syngeneic transplant will be allowed only if no history of, or currently active, Graft-Versus-Host Disease [GvHD]).
* Any major surgery within the last 4 weeks.
* Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria as described in inclusion criteria.
* Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures.
* History of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
* Evidence of active mucosal or internal bleeding.
* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. (Stable chronic liver disease [including Gilbert's syndrome or asymptomatic gallstones] or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria)
* Participants with previous or concurrent malignancies other than multiple myeloma are excluded, unless the second malignancy has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. (Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction).
* Evidence of cardiovascular risk including any of the following: Evidence of current clinically significant uncontrolled arrhythmias including clinically significant electrocardiogram (ECG) abnormalities including 2nd degree (Mobitz Type II) or 3rd degree atrioventricular block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening; Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; Uncontrolled hypertension.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin, pomalidomide, dexamethasone or any of the components of the study intervention.
* Pregnant or lactating female.
* Active infection requiring treatment.
* Known human immunodeficiency virus (HIV), unless the participant can meet all of the following criteria: Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/mL; CD4+ T-cell (CD4+) counts =350 cells/uL; No history of AIDS-defining opportunistic infections within the last 12 months.(Consideration must be given to ART and prophylactic antimicrobials that may have a drug-drug interaction and/or overlapping toxicities with belantamab mafodotin or other combination products as relevant)
* Participants with Hepatitis B will be excluded unless the following criteria can be met: If the participant is hepatitis B core antibody (HbcAb) positive or hepatitis B surface antigen (HbsAg) negative, then hepatitis B virus (HBV) deoxyribonucleic acid (DNA) should be undectectable at the time of screening; If HbsAg+ at screening or <=3 months prior to first dose of study treatment, then HBV DNA should be undetectable, highly effective antiviral treatment should be started =4 weeks prior to first dose of study treatment, exclusion of participants with cirrhosis and participants in Japan must test hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb ).
* Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria: Hepatitis C RNA test negative at Screening and successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period of at least 4 weeks (Hepatitis RNA is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing).
* Participants unable to tolerate thromboembolic prophylaxis.
* Current corneal epithelial disease except for mild punctate keratopathy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/04/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/06/2025
Actual
Sample size
Target
Accrual to date
Final
325
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Gosford
Recruitment hospital [2] 0 0
GSK Investigational Site - Liverpool
Recruitment hospital [3] 0 0
GSK Investigational Site - St Leonards
Recruitment hospital [4] 0 0
GSK Investigational Site - Woodville
Recruitment hospital [5] 0 0
GSK Investigational Site - Hobart
Recruitment hospital [6] 0 0
GSK Investigational Site - Clayton
Recruitment hospital [7] 0 0
GSK Investigational Site - Fitzroy
Recruitment hospital [8] 0 0
GSK Investigational Site - Geelong
Recruitment hospital [9] 0 0
GSK Investigational Site - Nedlands
Recruitment hospital [10] 0 0
GSK Investigational Site - St. Albans
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2065 - St Leonards
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
7000 - Hobart
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
3065 - Fitzroy
Recruitment postcode(s) [8] 0 0
3220 - Geelong
Recruitment postcode(s) [9] 0 0
6009 - Nedlands
Recruitment postcode(s) [10] 0 0
03021 - St. Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Nebraska
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Oregon
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Wisconsin
Country [10] 0 0
Belgium
State/province [10] 0 0
Brugge
Country [11] 0 0
Belgium
State/province [11] 0 0
Bruxelles
Country [12] 0 0
Belgium
State/province [12] 0 0
Edegem
Country [13] 0 0
Belgium
State/province [13] 0 0
Jette
Country [14] 0 0
Belgium
State/province [14] 0 0
Kortrijk
Country [15] 0 0
Belgium
State/province [15] 0 0
Yvoir
Country [16] 0 0
Brazil
State/province [16] 0 0
Ceará
Country [17] 0 0
Brazil
State/province [17] 0 0
Paraná
Country [18] 0 0
Brazil
State/province [18] 0 0
Rio Grande Do Sul
Country [19] 0 0
Brazil
State/province [19] 0 0
Rio de Janeiro
Country [20] 0 0
Brazil
State/province [20] 0 0
São Paulo
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Pleven
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
China
State/province [25] 0 0
Guangdong
Country [26] 0 0
China
State/province [26] 0 0
Jiangsu
Country [27] 0 0
China
State/province [27] 0 0
Jiangxi
Country [28] 0 0
China
State/province [28] 0 0
Jilin
Country [29] 0 0
China
State/province [29] 0 0
Beijing
Country [30] 0 0
China
State/province [30] 0 0
Chengdu
Country [31] 0 0
China
State/province [31] 0 0
Hangzhou
Country [32] 0 0
China
State/province [32] 0 0
Tianjin
Country [33] 0 0
China
State/province [33] 0 0
Zhengzhou
Country [34] 0 0
France
State/province [34] 0 0
Le Mans
Country [35] 0 0
France
State/province [35] 0 0
Montpellier
Country [36] 0 0
France
State/province [36] 0 0
Poitiers cedex
Country [37] 0 0
Germany
State/province [37] 0 0
Baden-Wuerttemberg
Country [38] 0 0
Germany
State/province [38] 0 0
Berlin
Country [39] 0 0
Germany
State/province [39] 0 0
Hamburg
Country [40] 0 0
Greece
State/province [40] 0 0
Athens
Country [41] 0 0
Greece
State/province [41] 0 0
Haidari, Athens
Country [42] 0 0
Greece
State/province [42] 0 0
Larisa
Country [43] 0 0
Greece
State/province [43] 0 0
Patra
Country [44] 0 0
Greece
State/province [44] 0 0
Thessaloniki
Country [45] 0 0
Hungary
State/province [45] 0 0
Budapest
Country [46] 0 0
Hungary
State/province [46] 0 0
Debrecen
Country [47] 0 0
Hungary
State/province [47] 0 0
Kaposvár
Country [48] 0 0
Hungary
State/province [48] 0 0
Nyiregyhaza
Country [49] 0 0
Italy
State/province [49] 0 0
Calabria
Country [50] 0 0
Italy
State/province [50] 0 0
Emilia-Romagna
Country [51] 0 0
Italy
State/province [51] 0 0
Lazio
Country [52] 0 0
Italy
State/province [52] 0 0
Lombardia
Country [53] 0 0
Italy
State/province [53] 0 0
Puglia
Country [54] 0 0
Italy
State/province [54] 0 0
Toscana
Country [55] 0 0
Italy
State/province [55] 0 0
Umbria
Country [56] 0 0
Italy
State/province [56] 0 0
Milano
Country [57] 0 0
Japan
State/province [57] 0 0
Aichi
Country [58] 0 0
Japan
State/province [58] 0 0
Chiba
Country [59] 0 0
Japan
State/province [59] 0 0
Ehime
Country [60] 0 0
Japan
State/province [60] 0 0
Fukushima
Country [61] 0 0
Japan
State/province [61] 0 0
Gifu
Country [62] 0 0
Japan
State/province [62] 0 0
Gunma
Country [63] 0 0
Japan
State/province [63] 0 0
Hokkaido
Country [64] 0 0
Japan
State/province [64] 0 0
Kyoto
Country [65] 0 0
Japan
State/province [65] 0 0
Osaka
Country [66] 0 0
Japan
State/province [66] 0 0
Tokyo
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Goyang-si, Gyeonggi-Do
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Hwasun
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Incheon
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Seongnam-si, Gyeonggi-do
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Seoul
Country [72] 0 0
Netherlands
State/province [72] 0 0
Amersfoort
Country [73] 0 0
Poland
State/province [73] 0 0
Gdansk
Country [74] 0 0
Poland
State/province [74] 0 0
Krakow
Country [75] 0 0
Poland
State/province [75] 0 0
Torun
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Ekaterinburg
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Kaluga
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Kirov
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Krasnoyarsk
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Nizhny Novgorod
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Novosibirsk
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Saint Petersburg
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Samara
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Sochi
Country [86] 0 0
Russian Federation
State/province [86] 0 0
St'Petersburg
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Syktyvkar
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Tula
Country [89] 0 0
Spain
State/province [89] 0 0
Badalona
Country [90] 0 0
Spain
State/province [90] 0 0
Barcelona
Country [91] 0 0
Spain
State/province [91] 0 0
Malaga
Country [92] 0 0
Spain
State/province [92] 0 0
Pamplona
Country [93] 0 0
Spain
State/province [93] 0 0
Pozuelo De Alarcón/Madrid
Country [94] 0 0
Spain
State/province [94] 0 0
Salamanca
Country [95] 0 0
Spain
State/province [95] 0 0
Santiago de Compostela
Country [96] 0 0
Spain
State/province [96] 0 0
Valencia
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Lanarkshire
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Staffordshire
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Dundee
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Edinburgh
Country [101] 0 0
United Kingdom
State/province [101] 0 0
London
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Nottingham
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Oxford
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04162210